Kollol Pal

This inventor holds 10 USPTO granted patents and 7 published patent applications, plus 1 CIPO patent and 1 EPO patent. Top assignees: Pyramid Biosciences, Inc, Medisyn Technologies, Inc., Boston University. Active years: 1998-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Kollol Pal. Retrieved from https://idiyas.com/inventor/kollol-pal

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 10 (Patent Applications = 7)

% Patents Active = 60.0

CIPO Patents = 1

EPO Patents = 1 (Patent Applications = 2)

Average Co-Inventor Count = 4.1

ph-index = 4

Forward Citations = 91(Granted Patents)

Company Filing History:

4 out of 4

Pyramid Biosciences, Inc

patents

2 out of 3

Medisyn Technologies, Inc.

Satori Pharmaceuticals, Inc.

patents

Years Active: 1998-2026

Loading Chart...

10 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12606565 - Methods for preparing tyrosine receptor kinase inhibitors (2026-04-21),

2. 12486276 - 5-(2,5-difluorophenyl)pyrrolidin-1-yl)-3-(1H-pyrazol-1-yl)pyrazolo[1,5-a]pyrimidine derivatives and related compounds as Trk kinase inhibitors for treating cancer (2025-12-02),

3. 11739096 - 5-(2,5-difluorophenyl)pyrrolidin-1-yl)-3-(1H-pyrazol-1-yl)pyrazolo [1,5-A]pyrimidine derivatives and related compounds as Trk kinase inhibitors for treating cancer (2023-08-29),

4. 11230546 - 5-(2,5-difluorophenyl)pyrrolidin-1-yl)-3-(1h-pyrazol-1-yl)pyrazolo[1,5-a]pyrimidine derivatives and related compounds as Trk kinase inhibitors for treating cancer (2022-01-25),

5. 9155792 - RecA inhibitors with antibiotic activity, compositions and methods of use (2015-10-13),

6. 8088785 - Therapeutic compound and treatments (2012-01-03),

7. 7851641 - Compounds useful for treating neurodegenerative disorders (2010-12-14),

8. 7652029 - Therapeutic compound and treatments (2010-01-26),

9. 6423519 - Compositions and methods for inhibiting fungal growth (2002-07-23),

10. 5733920 - Inhibitors of cyclin dependent kinases (1998-03-31),

Title: Innovator Kollol Pal: Advancements in Trk Kinase Inhibitors

Introduction

Kollol Pal is an accomplished inventor based in Needham, MA, USA, with a remarkable portfolio of 8 patents. His innovative research focuses on the development of pharmaceutical compounds aimed at treating cancer and inflammatory diseases, particularly through the targeting of Trk kinases.

Latest Patents

Among his latest contributions to the field, Kollol Pal has developed 5-(2,5-difluorophenyl)pyrrolidin-1-yl)-3-(1H-pyrazol-1-yl)pyrazolo[1,5-A]pyrimidine derivatives. These compounds serve as Trk kinase inhibitors, offering potential therapeutic avenues for cancer treatment. The applications involve complex formulations designed to inhibit Trk kinases associated with various diseases and disorders, specifically detailed in the formula provided in his patents.

Career Highlights

Throughout his career, Kollol Pal has been associated with prominent biotech companies, including Pyramid Biosciences, Inc. and Medisyn Technologies, Inc. His work in these organizations has been instrumental in advancing research and the development of new therapeutic strategies. He has consistently focused on creating impactful solutions in the medical field through his inventive mindset and expertise.

Collaborations

Kollol has worked alongside talented colleagues like Stephane Ciblat and Vincent Albert. Their collaborative efforts reflect the synergy and teamwork essential in the innovative processes within biopharmaceutical research and development.

Conclusion

Kollol Pal's commitment to innovation and his contributions to the field of cancer treatment through his patent work underscore his significance as an inventor. His developments in Trk kinase inhibitors are paving the way for new therapeutic options, demonstrating the importance of scientific collaboration and inventiveness in addressing critical health challenges.

Profile summary based on public USPTO records.